SCHEMBL7794333

SCHEMBL7794333

CCCCNC(=O)Nc1nc(Cc2ccc3c(c2)OCO3)c2c(N)c(Cl)ccc2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.45
KDM4E B2RXH2 4/20 0.45
MEN1 O00255 4/20 0.45
ALDH1A1 P00352 3/20 0.45
GAA P10253 3/20 0.45
MAPT P10636 2/20 0.45
NSD2 O96028 1/20 0.45
THRB P10828 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
CHRM4 P08173 2/20 0.40
HPGD P15428 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TRPV1 Q8NER1 1/20 0.38
HSP90AB1 P08238 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
PPARG P37231 1/20 0.38
NCOA2 Q15596 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7794741 0.89 CHRM4 (0.42) KMT2AKDM4EMEN1ALDH1A1MAPT
SCHEMBL7797440 0.80 HSP90AB1 (0.40) KMT2AKDM4EMEN1ALDH1A1MAPT
SCHEMBL7797896 0.80 HSP90AB1 (0.51) ALDH1A1CHRM4HSD17B10HSP90AB1LTB4R
SCHEMBL8862704 0.76 LTB4R (0.46) ALDH1A1CHRM4HSD17B10HSP90AB1LTB4R
SCHEMBL27379780 0.76 SLC2A1 (0.47) ALDH1A1HSD17B10HSP90AB1LTB4R
SCHEMBL27355398 0.76 ALDH1A1 (0.43) KMT2AKDM4EMEN1ALDH1A1MAPT
SCHEMBL9094776 0.75 LTB4R (0.41) ALDH1A1CHRM4HSD17B10HSP90AB1LTB4R
SCHEMBL7497969 0.74 PDE4A (0.56) KMT2AMEN1ALDH1A1TRPV1POLB
SCHEMBL27382274 0.73 CHRM4 (0.39) KMT2AKDM4EMEN1ALDH1A1GAA
SCHEMBL27364630 0.72 CHRM4 (0.38) KMT2AKDM4EMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010031760-A1 Method of treating a patient having precancerous lesions with quinazoline derivatives PAMUKCU RIFAT (US) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031760-A1 Method of treating a patient having precancerous lesions with quinazoline derivatives MKI67, PCNA, NQO2 KMT2A 1203/4885KDM4E 3242/4885MEN1 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.